|
(Health-NewsWire.Net, May 01, 2015 ) Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Complete report on H1, 2015 Pipeline Review of “Malignant Glioma” addiction with 27 market data tables and 15 figures, spread across 87 pages is available at http://www.rnrmarketresearch.com/malignant-glioma-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope:
• The report provides a snapshot of the global therapeutic landscape of Malignant Glioma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=269578 .
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Malignant Glioma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
More reports on Cancer Drugs :
Ondansetron – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)
Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. ! NOW WITH ‘USA VIEW’!
This report covers:
International Nonproprietary Name: Ondansetron
Indications: Emesis; Postoperative nausea and vomiting
Innovator:GlaxoSmithKline (Zofran)
Complete report is available at http://www.rnrmarketresearch.com/ondansetron-patent-extension-and-data-exclusivity-expiry-snapshot-50-countries-market-report.html
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
